Antibody-based cancer treatment updates will be among the stars of the show for myeloma physicians and researchers attending the American Society of Hematology (ASH) annual meeting in Atlanta, GA from December 11-14, 2021. For patients around the world too.
A Is for Antibodies in Myeloma: Insights and Patient Voices Along the Therapeutic Journey, a symposium featuring three leading myeloma experts, will be among many professional presentations held the day before the official ASH opening that has become known as “Super Friday.” Scheduled for Friday, December 10 from 7:00-9:00 am Eastern Standard Time, the program will feature:
Recent and expected FDA drug approvals of antibody-based approaches have been shown to provide durable efficacy in many different clinical settings. As the therapeutic benefits of specific targets are better understood, the time for combining them for greater efficacy is fast approaching.
This event will help viewers to better understand the alphabet soup of targets—BCMA, CD38, SLAMF7, GPRC5D, FCRH5—that are key to their treatment today and even more important in the future.
The HealthTree Foundation is partnering with PeerView, a company specializing in professional continuing medical education programs for a variety of cancers, and Medical Learning, Inc. to host the symposium.
Myeloma Coaches will be featured in brief videos following each speaker’s presentation to provide their perspectives on how treatment with novel antibodies impacted their lives.
Suzanne Lentzsch, MD, PhD, is Professor of Clinical Medicine and the Director of the Multiple Myeloma and Amyloidosis Service at the Columbia University Medical Center in New York. Her translational research focuses on identifying novel targets for the treatment of myeloma, myeloma bone disease, and AL amyloidosis. Dr. Lentzsch is a member of the National Cancer Institute’s Myeloma Steering Committee, the SWOG Myeloma Working Group, co-chairs the International Myeloma Society’s Career Development Committee, and serves as a grant reviewer for the Leukemia and Lymphoma Society and Stand Up 2 Cancer (SU2C) in collaboration with the American Association for Cancer Research. She will begin a four-year term in 2021 on the American Society of Hematology’s Scientific Committee on Plasma Cell Neoplasia and as Associate Editor for the Journal of Clinical Oncology. Prior to joining Columbia University, Dr. Lentzsch served as Clinical Director of the Multiple Myeloma Program at the University of Pittsburgh Cancer Institute (UPCI). She served a research fellowship to study the mechanism of action of thalidomide and its derivatives in multiple myeloma under the mentorship of Dr. Kenneth Anderson at the Dana-Farber Cancer Institute in Boston. She completed a fellowship and residency at the Humboldt University/Charité Berlin, Germany, where she earned her MD.
Noa Biran, MD, is an associate professor in the Myeloma Division of the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey. She is actively involved in clinical research with a focus on high-risk disease and the role of minimal residual disease in multiple myeloma. Dr. Biran has presented a range of clinical work at international and national conferences such as the American Society of Hematology and the Society of Hematologic Oncology. She is widely published in hematology and oncology journals such as the American Journal of Hematology, Current Hematologic Malignancy Reports, and The Hemophilia Report. She has also co-authored the chapter “Oncologic Emergencies” in Essentials of Hospital Medicine: A Practical Guide for Clinicians. Prior to joining the John Theurer Cancer Center faculty, Dr. Biran served as Chief Fellow of Hematology and Medical Oncology at Icahn School of Medicine at Mount Sinai, New York. She also practiced in their internal medicine internship and residency and participated in numerous lecture series and training sessions for medical students, residents, and nurse practitioners. She received her medical degree from The George Washington University in Washington, D.C.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113